Demirkan Burcu, Guray Yesim, Guray Umit, Korkmaz Sule
Yüksek Ihtisas Hospital, Cardiology Clinic, Ankara, Turkey.
J Thromb Thrombolysis. 2006 Aug;22(1):77-8. doi: 10.1007/s11239-006-7789-1.
Although the glycoprotein IIb/IIIa receptor inhibitors have improved outcomes of patients with acute coronary syndrome (ACS), therapy with these agents may cause thrombocytopenia with bleeding complications. This adverse effect is seemed to be rare with tirofiban. In this report, we describe a case of acute profound thrombocytopenia within two hours of tirofiban administration and review the differential diagnosis and the management of thrombocytopenia.
尽管糖蛋白IIb/IIIa受体抑制剂改善了急性冠状动脉综合征（ACS）患者的预后，但使用这些药物进行治疗可能会导致血小板减少并伴有出血并发症。替罗非班似乎很少出现这种不良反应。在本报告中，我们描述了1例在使用替罗非班后两小时内发生急性严重血小板减少的病例，并对血小板减少的鉴别诊断和管理进行了综述。
